Price T Rowe Associates Inc. MD Trims Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Price T Rowe Associates Inc. MD lowered its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 29.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,781,268 shares of the company's stock after selling 734,635 shares during the period. Price T Rowe Associates Inc. MD owned 1.47% of 10x Genomics worth $25,580,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Barclays PLC grew its holdings in 10x Genomics by 11.7% during the 3rd quarter. Barclays PLC now owns 602,536 shares of the company's stock worth $13,605,000 after acquiring an additional 63,079 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after purchasing an additional 277,355 shares during the period. Diversified Trust Co bought a new position in 10x Genomics during the 4th quarter worth $511,000. Green Alpha Advisors LLC acquired a new position in 10x Genomics during the 4th quarter worth about $355,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of 10x Genomics in the 4th quarter valued at about $26,308,000. Institutional investors own 84.68% of the company's stock.

Analyst Upgrades and Downgrades

TXG has been the topic of a number of recent analyst reports. UBS Group cut their price objective on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Leerink Partnrs lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. lowered their target price on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. Barclays lowered their price objective on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Finally, Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and cut their target price for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $18.85.

10x Genomics Trading Up 4.1 %

Shares of NASDAQ:TXG traded up $0.33 during mid-day trading on Friday, hitting $8.43. 3,188,259 shares of the company traded hands, compared to its average volume of 2,261,416. The stock has a 50-day moving average price of $9.17 and a two-hundred day moving average price of $12.79. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $28.25. The stock has a market cap of $1.03 billion, a P/E ratio of -5.55 and a beta of 2.01.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan Mateo purchased 40,000 shares of the firm's stock in a transaction dated Friday, February 21st. The shares were bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the purchase, the director now owns 61,691 shares in the company, valued at $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 10.03% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.